KEY DETAILS
Novo Nordisk reports no supply disruptions for Ozempic in Canadian pharmacies.
A study of US adults with diabetes found no measurable change in mental health, work or marriage after starting a GLP-1, while a separate study of women using them for weight loss found large gains in employment.
Experts share three stylish haircut options for those noticing thinning hair on GLP-1s.
At a bail hearing, the lawyer for a Bondi man charged with murder said his client had side effects from Ozempic and asked for psychiatric assessments.
Reports show Ozempic use is spreading among sorority members pursuing thinness.
Novo Nordisk confirmed today that Ozempic supply across Canadian pharmacies remains stable, with no disruptions reported. For patients who have weathered shortages before, that stability matters. But the day's other stories show how complicated life on these drugs has become outside the pharmacy counter, touching everything from economic research to campus culture to a courtroom in Australia.
Novo Nordisk's advisory today addressed a concern that has lingered since the shortages of 2022 and 2023, when Canadian patients often struggled to fill Ozempic prescriptions on schedule. The company states that pharmacies across the country currently have adequate stock and that it is not aware of any regional gaps. For patients managing type 2 diabetes, that kind of reassurance carries real weight, since missed doses can disrupt blood sugar control. Whether that stability holds through the coming months remains to be seen, but for now, the supply chain in Canada appears steady.
That steadiness in the diabetes care system is worth setting alongside a new economic analysis of GLP-1 drugs more broadly. Using national survey data from 2012 to 2023, researchers found that adults with diabetes who started a GLP-1 showed no measurable change in mental health, self-rated health, employment or marital status. The study did not measure blood sugar or other diabetes outcomes, and it has not been peer reviewed. A separate 2026 paper on women using GLP-1s for weight loss found large gains in employment among women who were not working at the start. That gap between clinical benefit and broader impact is a useful check on some of the more sweeping claims made about these medications.
Away from clinical outcomes, some patients on GLP-1 medications are dealing with a more visible side effect: thinning hair. Hairstylists and dermatology experts have started offering practical advice rather than just sympathy, and three haircut approaches have emerged as favorites for people managing this change. Shorter cuts, layered styles, and cuts that add volume near the roots were all recommended as ways to make thinning hair less noticeable day to day. It is a small example of how attention around these drugs has expanded well past prescriptions, into styling and self-care advice tailored specifically to GLP-1 users.
Ozempic came up in a far more serious setting in an Australian court. At a bail hearing, the defence lawyer for a 47-year-old Bondi Beach man charged with murdering a 90-year-old woman said his client had been having side effects from Ozempic and asked for psychiatric assessments. The court made no finding on that point. Cases like this remain rare, and there is no established medical evidence linking Ozempic to violent behavior. Still, the fact that it was raised at all in a murder case signals how far these medications have entered everyday conversations, for better or worse.
That same cultural reach appears in a different setting: college sororities, where reports indicate Ozempic use is spreading among members pursuing thinness rather than managing diabetes or obesity. Off-label use for weight loss is not new, but its presence in sorority culture points to how quickly these drugs have moved beyond medical necessity into social pressure around appearance. For young women already contending with body image expectations, that shift raises questions about access, cost, and long-term health that go beyond weight loss alone. It is a pattern worth watching as more reporting emerges on off-label use among younger, healthier populations.
Taken together, these stories point to a simple reality: Ozempic and similar drugs now operate on two very different levels. On one level, there is the clinical and supply side, where stability in Canada and measured economic outcomes give patients and doctors a clearer picture of what these medications actually do. On the other, there is everything happening around that clinical reality, in courtrooms and sorority houses and salon chairs, where the drugs' cultural footprint keeps growing faster than the research can keep pace with. If you or someone you know is using a GLP-1 medication, it may help to separate those two levels when making decisions, and to talk with a doctor about what the evidence actually supports rather than what is circulating in conversation.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.